Abstract

Gastroparesis is a disorder of gastric function characterized by delay in gastric emptying, frequently associated with chronic nausea and vomiting, early satiety, postprandial fullness, abdominal pain, and malnutrition that may require nutritional support. The broad objectives of this proposal is to improve our understanding of this disorder and advancing the diagnosis and treatment of gastroparesis and related disorders. We propose to do this through three specific aims, as follows:
Specific Aim 1 : To maintain, expand, and refine the Gastroparesis Registry in order to enable critical additional and new analyses of the clinical data and biosamples.
Specific Aim 2 : To conduct a randomized controlled trial of aprepitant in patients with gastroparesis and functional dyspepsia-postprandial distress syndrome.
Specific Aim 3 : To conduct a pilot and feasibility trial of a potential disease modifying approach using pioglitazone in patients with gastroparesis

Public Health Relevance

Gastroparesis has a devastating impact on quality of life and predominantly affects younger women. This research will help find new ways to diagnose and treat this conditon as well as related disorders characterized by nausea and vomiting.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01DK073983-15S1
Application #
10232645
Study Section
Special Emphasis Panel (ZDK1)
Program Officer
Serrano, Jose
Project Start
2006-04-15
Project End
2021-08-31
Budget Start
2020-09-01
Budget End
2021-08-31
Support Year
15
Fiscal Year
2020
Total Cost
Indirect Cost

  Institution

Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21205

  Publications

Hasler, W L; May, K P; Wilson, L A et al. (2018) Relating gastric scintigraphy and symptoms to motility capsule transit and pressure findings in suspected gastroparesis. Neurogastroenterol Motil 30:
Pasricha, Pankaj J; Yates, Katherine P; Sarosiek, Irene et al. (2018) Aprepitant Has Mixed Effects on Nausea and Reduces Other Symptoms in Patients With Gastroparesis and Related Disorders. Gastroenterology 154:65-76.e11
Parkman, H P; Hallinan, E K; Hasler, W L et al. (2017) Early satiety and postprandial fullness in gastroparesis correlate with gastroparesis severity, gastric emptying, and water load testing. Neurogastroenterol Motil 29:
Grover, M; Bernard, C E; Pasricha, P J et al. (2017) Diabetic and idiopathic gastroparesis is associated with loss of CD206-positive macrophages in the gastric antrum. Neurogastroenterol Motil 29:
Koch, K L; Hasler, W L; Yates, K P et al. (2016) Baseline features and differences in 48 week clinical outcomes in patients with gastroparesis and type 1 vs type 2 diabetes. Neurogastroenterol Motil 28:1001-15
Pasricha, Pankaj Jay; Snape, William (2016) Toward a Better Drug for Gastroparesis: The Problem With a Moving Target. Gastroenterology 151:20-2
Harer, Kimberly N; Pasricha, Pankaj J (2016) Chronic Unexplained Nausea and Vomiting or Gastric Neuromuscular Dysfunction (GND)? An Update on Nomenclature, Pathophysiology and Treatment, and Relationship to Gastroparesis. Curr Treat Options Gastroenterol 14:410-419
Parkman, H P; Hallinan, E K; Hasler, W L et al. (2016) Nausea and vomiting in gastroparesis: similarities and differences in idiopathic and diabetic gastroparesis. Neurogastroenterol Motil 28:1902-1914
Pasricha, Pankaj Jay (2015) Hunger games: is your stomach making you fat? Gastroenterology 148:491-3
Pasricha, Pankaj Jay (2015) Future directions in the treatment of gastroparesis. Gastroenterol Clin North Am 44:185-9

Showing the most recent 10 out of 35 publications